Physician profile
James Ferlmann
NPI 1558369371
$2,826.39
in general payments reported to CMS, 2019-2025
14 companies · $63.16 in 2025
The $63.16 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2021: $1,813 · 2022: $265 · 2023: $284 · 2024: $182 · 2025: $63.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $1,650.00 | 2021 | |
| Abbvie INC. | $357.15 | 2021-2023 | |
| Kerecis Limited | $303.87 | 2021-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Mentor Worldwide LLC | $181.87 | 2019 | |
| Next Science LLC | $114.27 | 2023 | Surgx, Xperience, Blastx |
| Smith+Nephew, INC. | $49.46 | 2021-2024 | Collagenase Santyl, Regranex |
| Sientra, INC. | $36.94 | 2019 | |
| Kci USA, INC. | $27.55 | 2023 | Activ.A.C., Promogran, V.A.C. Dermatac |
| Coloplast Corp | $26.61 | 2024 | |
| Organogenesis INC. | $22.05 | 2025 | Puraply Wound Matrix |
| Bioventus LLC | $15.09 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.50 | 2024 | Nuzyra |
| Hartmann USA, INC. | $13.63 | 2024 | Zetuvit Plus 10x10 P10 |
| Tactile Systems Technology INC | $13.40 | 2023 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ferlmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.